Introduction
Long-term repopulating hematopoietic stem cells (HSCs) have durable self-renewal properties and multilineage potential, and can thus serve as lifelong reservoir for all blood cells 1 
.
Hematopoietic stem and progenitor cell (HSPC) transplantation is the most established cellular replacement therapy for hematological and other conditions. However, the limited availability of HLA-matched donors and the associated severe acute and chronic complications significantly restrict allogeneic treatment options. In gene therapy applications, sufficient autologous HSPCs are not available for genetic modification in a wide variety of disorders, and methodologies for safe expansion of these rare cells are inexistent 2 . Induced pluripotent stem cell (iPSC)-based therapies are a promising alternative because of their potential to provide an unlimited source of autologous, patient-specific cells for transplantation. However, the stepwise addition of cytokines and morphogens used in most protocols to recapitulate the natural developmental process generally induces iPSCs to produce hematopoietic progenitors with limited engraftment and differentiation capability 3, 4 . The self-renewal and multilineage capacity of iPSC-derived hematopoietic cells can be enhanced by forced ectopic expression of hematopoietic transcription factors (TFs) 5, 6 . However, these protocols lack clinical relevance due to their low efficiency, poor scalability and the necessary use of integrating lentiviral vectors for constitutive expression of potentially oncogenic TFs.
In the developing mammalian embryo, blood is produced in consecutive waves [7] [8] [9] . The first wave of hematopoietic progenitors, dubbed "primitive", occurs in the yolk sac blood islands 10 .
This primitive program is highly restricted, resulting primarily in the emergence of large, nucleated CD235a + erythroid cells expressing embryonic globins, and in the production of some macrophage and megakaryocyte progenitors. A second wave of hematopoietic potential, termed "definitive", supplies lymphoid progenitor cells, as well as erythro-myeloid progenitors (EMPs) that produce red cells expressing predominantly adult-type ɣ-and β-globin molecules. The third wave is also considered "definitive" but is uniquely marked by the appearance of HSCs within the aorta-gonadmesonephros (AGM) region of the developing embryo 11, 12 . These cells are specified and bud off from hemogenic endothelium (HE), a distinct subset of vascular endothelium (VE) that directly changes fate into hematopoietic progenitors through a morphogenic process called endothelial-tohematopoietic transition (EHT) [13] [14] [15] . Thus, HE with definitive hematopoietic potential must emerge for the ex vivo production of engraftable HSCs from human iPSCs.
Definitive multilineage HSPCs were shown to arise from HE lining arteries, but not veins, during development 16, 17 . This observation evokes the possibility that arterial specification of HE is necessary to initiate the definitive HPSC program and exploitation of this concept may facilitate the ex vivo production of engraftable HSCs 18, 19 . However, this hypothesis has been challenged and arterial specification of HE, while necessary, may not be sufficient for definitive HPSC formation 18 . In addition, distinct cellular signaling pathways regulate the specification of primitive and definitive hematopoiesis in human iPSC cultures. Repression of nodal/activin signaling and activation of the WNT/β-catenin pathway in mesodermal precursors are required to downregulate primitive and enrich for definitive hematopoietic programs [20] [21] [22] . Simultaneous modulation of these pathways at day 2 of culture has been shown to activate arterial genes and restore expression of several key hematopoietic regulators within the HOXA gene cluster that are commonly downregulated during human pluripotent stem cell differentiation 21, 23 .
Most ex vivo methods for hematopoietic differentiation of iPSCs are based either on coculture with stromal cells or embryoid body (EB) formation 24 . Recently, an alternative simple, monolayerbased, chemically-defined, and scalable differentiation protocol requiring no replating, coculture 6 | Page or EB formation has become available (STEMdiff TM Hematopoietic Kit, STEMCELL Technologies, Inc.). During differentiation, a supportive adherent monolayer rapidly forms, followed by the emergence of suspension hematopoietic cells that can be harvested at regular intervals during culture for analysis. This approach reproducibly yields enriched populations of CD43 + CD45 + CD34 + hematopoietic progenitors with functional activity in the colony-forming unit (CFU) assay. The simplicity and efficiency of the protocol have enabled secondary applications, such as differentiation of microglia 25 and NK cells 26 , validation of CD34 fluorescent reporter human iPSC lines 27 , mapping of human pluripotent stem cell differentiation pathways 28 , and investigation of a posttranscriptional regulatory circuitry for the maintenance and differentiation of pluripotent stem cells and HSPCs 29 . In this study, we systematically examined the phenotype and function of supernatant and monolayer cells throughout differentiation, and provide evidence that this system can be adapted to move closer to a clinically-relevant protocol for the generation of definitive erythroid and multipotent hematopoietic progenitor cells.
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Methods
Generation and culture iPSCs
Peripheral blood CD34 + CD38cells mobilized from healthy donors were reprogrammed into iPSCs (MCND-TENS2 line) using the integration-free CytoTune 2.0 Sendai virus reprogramming kit (A16517, Thermo Fisher Scientific) following the method previously reported 30, 31 .
Pluripotency was confirmed by teratoma formation assay, G-banding karyotype and flow cytometry for TRA-1-60 and NANOG markers as previously described 32 . iPSCs were maintained on 6-well tissue culture plates thinly coated with Matrigel® (Corning, 354230) in Essential 8™ (E8) Medium (A1517001, ThermoFisher). Culture medium was changed daily and iPSCs were split every three to four days. Briefly, medium was aspirated and wells were sequentially washed with phosphate buffered saline (PBS) or 0.5 mM EDTA in PBS (PBS/EDTA). Cells were then dissociated in PBS/EDTA 0.5 mM for 2-3 minutes. PBS/EDTA was aspirated and replaced with 1 mL E8 medium containing 1.25 µM ROCK inhibitor (Y0503, Sigma). Cells were pipetted 3-4 times using a P1000 pipette to dissociate into small to medium sized clusters, and split onto new 6-well plates at various dilutions.
Hematopoietic differentiation of human iPSCs
iPSCs were differentiated for 21 days using the STEMdiff™ Hematopoietic Kit (05310, STEMCELL Technologies, Inc.). Briefly, one day (D) before differentiation (D-1), iPSCs were split as described above, and cluster concentrations were calculated. A total of 20-35 clusters were transferred per well into a Matrigel-coated 12-well plate and cultured overnight. On D0 of differentiation, medium A was added to promote mesodermal differentiation and a half medium A change was done on D2. In select experiments, WNT/β-catenin agonist CHIR99021 (SML1046, Sigma) and activin/nodal/TGFβ antagonist SB431542 (S4317, Sigma) were added on D2 at a final 8 | Page concentration of 3 µM for 24-36 hours. On D3 of differentiation, supernatant was removed and hematopoietic differentiation medium B was added, followed by half-medium change on day 5, 7, 10, 12, 14, 17, and 19. On days when medium was changed, supernatant and monolayer cells were harvested for analysis. To completely detach the monolayer and clusters of cells from the plastic surface, Accutase™ (07920, STEMCELL Technologies, Inc.) was added to each well for 10 minutes at 37°C and cells were vigorously pipetted up and down to ensure complete recovery.
Cells are then filtered through a 40 µM cell strainer, counted, and prepared for further analysis.
Flow Cytometry and Fluorescence-Activated Cell Sorting (FACS)
Cells were stained with antibodies (Table S1), following manufacturer's instructions and analyzed on an LSRII Fortessa analyzer (Becton Dickinson). For gene expression, CFU assays, MSC differentiation, and mouse transplantation studies, cell populations were sorted on a FACS Aria (Becton Dickinson) with a 100 µm nozzle.
Gene Expression by real-time qPCR
RNA was extracted and purified using directions of the RNeasy Micro Kit (74004, Qiagen). To assess HOXA gene expression, real-time qPCR was done using TaqMan RNA-to-Ct 1-Step Kit (4392653, Applied Biosystems) on a BioRad C1000 touch system and all samples were multiplexed to include an internal GAPDH control. For evaluation of globin expression, real-time qPCR was performed using the Quantstudio 6 system (ThermoFisher), with an α-globin reference gene and a plasmid containing alpha-theta-epsilon-gamma-beta sequences in a 1:1:1:1:1 ratio for normalization of expression, as previously described 33 . Primers and probes used for real-time qPCR are listed in Table S2 . Error bars were calculated using SEM for ΔΔCT values to calculate the upper and lower boundaries of the 95% confidence interval, which were then log transformed 9 | Page in the same way as the mean (2 -ΔΔCT ). Two-way unpaired Student's t-tests were done on untransformed ΔCT values.
CFU Assays
Human CFU assays were performed as per manufacturer's instructions (04445, STEMCELL Technologies, Inc.). Briefly, 9,000 and 4,500 total supernatant cells for control and CHIR/SB samples, respectively, were suspended in 300 uL of DMEM/2% FBS, which was then added to the methocult tube and vortexed. Following 5 minutes to allow for bubble dissipation, 1.1 mL of the medium was plated onto 35 x 10 mm style tissue-culture dishes (353001, Corning) for 1,500 to 3,000 cells per plate. Colonies were scored 17-20, and 14 days following plating for control and CHIR/SB samples, respectively. 
NSG mouse transplantation
2.7.Mesenchymal stromal cell (MSC) differentiation
To confirm MSC identify, CD43 -CD45monolayer cells were sorted at various days of culture and differentiated per manufacturer's instructions into adipocytes (A1007001, Thermo Fisher Scientific), chondrocytes (A1007101, Thermo Fisher Scientific), and osteocytes (A1007201, Thermo Fisher Scientific). For comparison, control MSCs derived from the bone marrow of a healthy individual were differentiated following the same procedures.
Erythroid differentiation
For determination of globin chain composition, supernatant and monolayer cells were collected at day 7 and 17 of culture, and differentiated toward the erythroid lineage as previously described 33, 34 . Briefly, cells were cultured on irradiated OP9 cells (American Type Culture Collection (ATCC)) in Medium B with the addition of 5 U/mL erythropoietin (EPO; Amgen) and 5 ng/mL interleukin-3 (IL3; R&D Systems). Two days later, the floating cells were transferred into freshly irradiated OP9 feeder plates using an erythroid expansion media based on Iscove's Modified Dulbecco's Medium (IMDM; Sigma Aldrich) supplemented with 10 ng/mL stem cell factor (SCF; R&D Systems), 1 ng/mL IL3, 2 U/mL EPO, 1 µM estradiol (Pfizer), 1 µM dexamethasone (VETone, Boise), and 20% Knockout Serum Replacement (KSR, Thermo Fisher Scientific). Five days later, the medium was changed to a maturation erythroid medium containing IMDM, 2% bovine serum albumin (BSA; Roche), 0.56 mg/mL transferrin (Sigma Aldrich), 2 mM L-glutamine (Thermo Fisher Scientific), 2 U/mL EPO, 10 ng/mL insulin (Lilly), and 20% KSR, and the cells were cultured for another 8 to 10 days.
Reverse phase-high performance liquid chromatography (RP-HPLC)
The globin protein content of differentiated erythroid cells was evaluated by RP-HPLC as previously described 33, 35 . Briefly, erythroid cells were harvested and washed 3 times with PBS followed by a lysis step using HPLC grade water. The lysates were mixed with 10% of 100 mM Tris (2-carboxyethyl) phosphine (TCEP, Thermo Fisher Scientific) and incubated for 5 minutes.
Then, the lysates plus TCEP were mixed 1:1 with a solution containing 0.1% trifluoroacetic acid (TFA) and 32% acetonitrile (Honeywell Burdick & Jackson). The mixtures were centrifuged at 16,000g for 5 minutes and the supernatant was injected in an Agilent 1100 HPLC (Agilent Technologies) equipped with a reverse phase column, Aeris 3.6 µm Widepore C4 200Å (25034.6 mm, Phenomenex) with two solvents: solvent A, 0.12% TFA in water and solvent B, 0.08% TFA in acetonitrile using a flow of 0.7 mL per minute for 50 minutes.
Statistical Analysis
Results were analyzed with GraphPad Prism Software, using unpaired Student t-tests. Results are displayed as mean + SEM and * signifies p<0.05, ** p<0.01, *** p<0.001, and **** p<0.0001.
Results
Robust production of an adherent monolayer and supernatant hematopoietic cells during differentiation of human iPSCs.
Human iPSCs reprogrammed from CD34 + cells of a healthy volunteer ( Fig. S1 , A to C) were subjected to hematopoietic differentiation for 21 days using the STEMdiff™ monolayer approach.
In select experiments, we also explored the effects of adding the WNT/β-catenin agonist CHIR99021 (CHIR) and the activin/nodal/TGFβ antagonist SB431542 (SB), from differentiation day 2 to 3 ( Fig. 1A) . Under culture conditions that favored mesodermal specification (medium A, day 0 to 3), an adherent monolayer rapidly formed. With the subsequent addition of hematopoietic cytokines (medium B, day 3 to 21), hematopoietic clusters emerged from the monolayer before their eventual release in the supernatant fraction ( Fig. 1B) .
To systematically characterize the supernatant and monolayer cells arising from this system, both populations were collected at regular intervals between day 5 and 21 of differentiation ( ). In contrast, cells of the adherent monolayer formed a distinct population expressing neither markers (CD43 -CD45 -) (Fig. 1C ).
In the first phase of differentiation (day 5 to 9), the monolayer comprised most cells in culture with a modest relative contribution from the supernatant fraction ( Fig. 1D, E ). Between day 10 and 14, we observed an increase in percentages ( Fig. 1D ) and absolute numbers ( Fig. 1E ) of hematopoietic cells, and a concomitant decrease in the proportion of adherent cells likely resulting from an EHT process in culture. Supernatant hematopoietic cells were detected at a peak frequency of 69.1 ± 4.3% with an average yield of 1.1 ± 0.1x10 6 cells per 20-35 iPSC clusters (one well of a 12-well plate) at day 12 of culture. In the third stage of culture (day 15 to 21), both hematopoietic and monolayer fractions contributed equally (Fig. 1D ), but at a reduced total output (Fig. 1E ).
These data collectively show robust differentiation of human iPSCs into a supportive adherent monolayer from which hematopoietic clusters and suspension cells develop for up to 21 days in culture.
Successive emergence of hematopoietic populations in the culture supernatant during differentiation of human iPSCs
To determine whether hematopoietic differentiation of human iPSCs using the STEMdiff TM monolayer system can provide a suitable ex vivo model to study the emergence of hematopoiesis, we characterized the hematopoietic CD43 + CD45 +/supernatant fraction throughout differentiation by flow cytometry and functional assays.
We observed the formation of 3 successive populations of cells, as defined by expression of the CD34 hematopoietic progenitor cell marker. The first hematopoietic cells arising in the supernatant were predominantly CD34 -CD45with a distinct CD235a + erythroid phenotype. These cells peaked at day 7 and rapidly disappeared, evoking the transient nature of primitive erythroid cells that form during wave one of hematopoiesis in the developing embryo ( Fig. 2A, B) . The second population of suspension cells was enriched in CD34 hi CD45 lo multipotent HSPCs. The maximum production of these cells was observed at day 12 of differentiation, comprising 17.8 ± 0.6% of the supernatant cells and producing 1.7 ± 0.2 x 10 5 HSPCs per well ( Fig. 2A, B ). In the third phase of hematopoietic production, HSPCs gradually lost CD34 and upregulated expression of surface CD45, consistent with their progressive differentiation in extended cultures. By day 17 of culture, CD34 lo/-CD45 + cells accounted for 81.9 ± 1.9% of the supernatant fraction, with an average yield of 3.7 ± 0.2 x 10 5 cells per well, and this contribution persisted through day 21 ( Fig. 2A, B ).
We next sorted CD43 + CD45 +/supernatant cells to assess their multilineage differentiation potential in clonogenic progenitor assays. Colony-forming progenitors were detected throughout differentiation at frequencies ranging from 12.5 ± 4.8 to 30.3 ± 2.2 progenitors per 10 3 supernatant cells ( Fig. 2C) . At culture days when CD34 hi CD45 lo HSPCs were found to be most abundant by flow cytometry (day 10 to 14), both myeloid (CFU-G, CFU-M and CFU-GM) and erythroid (BFU-E and CFU-E) colony growth was observed. A progressive rise in BFU-E/CFU-E colonies was subsequently detected during culture, with a nearly exclusive erythroid contribution by day 21 (Fig. 2C) . To evaluate the developmental stage of erythroid progenitors, we quantified globin chains by RP-HPLC in RBCs differentiated from day 7 and day 17 supernatant cells ( Fig. 2D) . At day 7, embryonic (ɛ) globins prevailed, comprising 68.4 ± 2.6% of total β-globin series expression.
In contrast, red cells derived from day 17 suspension cells predominantly expressed adult-type ɣand β-globins, whereas ɛ-globins contributed much less compared with day 7 (11.1 ± 2.1% of βglobin series expression). These results were consistent with primitive (first wave) and definitive (second wave) hematopoiesis at day 7 and 17 of culture, respectively.
To determine whether the supernatant fractions at different stages of differentiation might contain hematopoietic cells with long-term repopulating potential, we first searched for cells with a CD34 + CD38 -CD45RA -CD90 + CD49f + phenotype which enables the highest reported purity of human HSCs 36 . Phenotypically defined HSCs (Fig. S2A) were detected in the culture supernatants primarily between day 10 and 14, with a maximum yield of 1.4 ± 0.5 x 10 4 cells per well at day 12 of differentiation ( Fig. 2E ). However, these cells did not result in efficient, long-term engraftment after transplantation in immuno-deficient (NSG) mice, consistent with the previously reported dissociation between stem cell repopulating function and cell surface phenotype in cultured cells ( Fig. S2B, left panel) 37 .
From these data, we infer that hematopoietic differentiation of human iPSCs with STEMdiff TM enables the sequential development of hematopoietic cells with features of primitive wave onehematopoiesis (peak at day 7), definitive multilineage HSPCs with potent colony formation activity in vitro but limited engraftment potential in vivo (peak at day 12), and definitive erythroidcommitted progenitors expressing adult-type globin chains (peak at day 17 to 21).
Abundant mesenchymal cells and limited arterial VE in the culture monolayer during human iPSC differentiation
To identify possible causes for the lack of durable repopulating potential of iPSC-derived HSPCs in this system, we sought to identify the cellular constituents of the CD43 -CD45adherent monolayer from which hematopoietic cells develop during differentiation. Because definitive HSPCs emerge from HE in close association with the VE 10,11 , we first queried whether cells of the monolayer expressed VE-defining markers, including VE-cadherin (CD144) and high levels of surface CD34 (CD144 + CD34 hi ). Non-hematopoietic cells expressing neither markers (CD144 -CD34 -) were recently shown to characterize a population of mesenchymal cells 38 .
We found that most cells comprising the adherent population throughout differentiation lacked CD144 and CD34 expression, representing up to 92.5 ± 2.5% of the monolayer at day 21. In contrast, CD144 + CD34 hi VE accounted for only a limited proportion of the monolayer, with a maximal contribution of 7.8 ± 2.0% at day 5 that steadily declined during culture (Fig. 3A, B) .
To further characterize the CD144 -CD34fraction, we assayed for expression of the surface markers CD90, CD73, and CD105, commonly used to identify mesenchymal stromal cells (MSCs), a major component of the adult BM niche. We observed a progressive increase in the percentage of cells with an MSC phenotype during differentiation (Fig. 3C, D) , contributing up to 61.5 ± 3.9% of the monolayer at day 21. Because MSCs characteristically differentiate to adipocytes, chondrocytes and osteocytes in vitro, we tested the trilineage differentiation potential of day 21 monolayer cells. In agreement with the observed MSC phenotype, we detected adipocytes, chondrocytes and osteocytes, although differentiation to adipocytes was more limited compared to control MSCs derived from primary BM specimens (Fig. 3E ).
Because HE and HSPCs are associated with arteries, not veins, in the developing embryo 19, 39, 40 , we next investigated whether arterial endothelium could be identified within the CD144 + CD34 hi VE population. Based on distinct expression of the surface markers CD184 and CD73, arterial and venous VE progenitors were previously reported to segregate to the CD73 mid CD184 + and CD73 hi CD184fractions, respectively 41 . We observed that CD73 hi CD184venous VE accounted for most of the CD144 + CD34 hi endothelial fraction of the monolayer throughout differentiation.
In contrast, low percentages of CD73 mid CD184 + arterial VE were detected only in the first phase of differentiation, with a maximal contribution of 3.6 ± 1.4% of the monolayer at day 7 of culture.
These cells subsequently declined and became undetectable after day 12 of differentiation ( Fig.   3F, G) . Thus, the limited arterial VE and the distinct abundance of mesenchymal cells within the adherent monolayer fraction could provide a sensible explanation for the lack of engraftment potential of iPSC-derived HSPCs in this system.
CHIR/SB molecules increase arterial VE in the adherent monolayer during the early phase of human iPSC differentiation
Because simultaneous modulation of nodal/activin and WNT/β-catenin pathways in mesodermal precursors was previously shown to activate arterial genes, restore expression of the hematopoietic HOXA gene cluster and promote definitive hematopoiesis 21, 23 , we examined the effect of supplementing the culture medium with the WNT/β-catenin agonist CHIR99021 (CHIR) and nodal/activin inhibitor SB431542 (SB) at day 2 of STEMdiff TM iPSC differentiation for a period of 30-36 hours (Fig. 1A) .
Addition of CHIR/SB led to a global increase in the percentages (Fig. 4A ) and numbers (Fig.   S3A ) of CD43 -CD45adherent monolayer cells on most days of differentiation compared to control cultures. In the early phase of differentiation, this increase stemmed primarily from a rise in VE formation (Fig. 4B ), and percentages of arterial ( Fig. 4C ) but not venous ( Fig. 4C ) VE increased in the presence of CHIR/SB. In addition, HOXA5, HOXA9 and HOXA10 transcription factors, previously shown to facilitate engraftment of iPSC-derived HSPCs 6 , were 2 to 4-fold more expressed in day 7 VE derived from CHIR/SB cultures compared to controls. However, the CHIR/SB-mediated effect on the production of VE was not sustained after day 7 of culture (Fig.   4B ), and CD144 -CD34mesenchymal cells continued to account for up to 95% of the adherent monolayer in the late phase of differentiation (Fig. 4F ).
CHIR/SB molecules suppress primitive hematopoiesis and promote definitive HSPC formation during human iPSC differentiation
We next investigated whether the early increase in VE formation observed in the presence of CHIR/SB influenced hematopoietic development. Addition of CHIR/SB led to an overall decrease in the percentages (Fig. 5A ) and numbers (Fig. S3B ) of supernatant hematopoietic cells relative to control cultures. As reported in other systems 22 , we observed CHIR/SB-mediated suppression of the primitive wave of CD34 -CD45 -CD235a + erythroid cells (Fig. 5B) , and a rise in percentages of CD34 hi CD45 lo definitive HSPCs (Fig. 5C ) with a concomitant reduction in percentages of CD34 lo/-CD45 + cells in late stages of differentiation compared to controls (Fig. 5D ). In colony forming assays, the frequency of progenitors with multilineage differentiation capacity was similar between sorted CHIR/SB and control supernatant cells at day 10 to 14 of culture (Fig. 5E ). In contrast, the progressive rise in BFU-E/CFU-E frequency previously observed from day 17 to 21 of the standard differentiation protocol was further enhanced by addition of CHIR/SB (Fig. 5E ). In RBCs differentiated from day 17 supernatant cells of CHIR/SB cultures, ɛ-globin expression was further decreased (5.8 ± 1.1% of total β-globin series expression) compared to controls (11.1 ± 2.1%), and a congruent increase in adult-type ɣand β-globins was observed (Fig. 5F ).
Next, we assessed whether CHIR/SB enabled the emergence of the third wave of definitive HSPCs with engraftment potential during iPSC differentiation. Phenotypically defined HSCs were readily detected at day 10 to 14 of differentiation at levels similar to control cultures (Fig. 5G ).
Addition of CHIR/SB also increased HOXA5, HOXA9 and HOXA10 expression 3 to 6-fold in supernatant cells harvested at day 12 compared to controls (Fig. 5H ). However, these cells did not sustain long-term hematopoietic engraftment in NSG mouse recipients (Fig. S2B, right panel) .
Together, these results indicate that addition of CHIR/SB during mesodermal specification suppresses primitive hematopoiesis, promotes the second wave of definitive hematopoiesis, but is insufficient to enable generation of functional HSCs.
Discussion
Spontaneous production of cells with properties of normal transplantable HSCs, independent of ectopic expression of potentially oncogenic transcription factors, has to date eluded the field. In this study, we systematically characterized an alternative monolayer-based culture system that may facilitate investigation of novel strategies for the differentiation of human iPSCs into fully functional HSCs. The utility of this approach hinges on its scalability for clinical and research applications, and its simple, adaptable experimental design requiring no replating, EB formation or coculture on stromal elements.
In the supernatant fraction, we observed transient production of primitive CD235a + erythroid cells followed by robust generation of HSPCs with clonogenic progenitor activity in vitro, a bona fide HSC immunophenotype (CD34 + CD38 -CD90 + CD45RA -CD49f + ), but no long-term engraftment potential in vivo. Thus, similar to other iPSC hematopoietic differentiation protocols, STEMdiff TM primarily recapitulates the first (primitive) and second (definitive) developmental wave of hematopoiesis observed in the yolk sac of developing embryos.
To understand the possible causes underpinning the absence of engraftable HSCs in this system, we examined the cellular constituents of the supportive adherent monolayer. We first identified a prevalent population of phenotypically defined mesenchymal cells throughout differentiation.
Perivascular mesenchymal cells are known to interact with HSPCs and maintain their activity in the adult BM niche 42 . However, their role in promoting HSPC development during ontogeny has not been demonstrated. Instead, mesenchymal cells have been implicated as components of the niche in the yolk sac controlling primitive erythroid cell maturation 43 . Further investigation is needed to fully understand whether these cells may offer inhibitory signals that preclude normal developmental switch to third wave definitive hematopoiesis during iPSC differentiation. We also found limited VE production and arterial specification within the adherent monolayer that may account for the lack of engrafting HSCs in culture. Indeed, recent advances propose that formation of these cells is restricted to arterial vessels during ontogeny 16, 17 . The arterial-specification model is supported in part by the demonstration of shared signaling requirements for both arterial identity acquisition and HSPC development [44] [45] [46] [47] [48] [49] [50] , and by the observation of selective impairment of hematopoiesis in the arteries of mice with knock-out of the artery-specific gene Ephrin B2 51, 52 .
Thus, in keeping with this model, arterial VE in the monolayer is likely inadequate to support the generation of bona fide engrafting HSCs in culture.
Our study provides proof-of-principle that the monolayer iPSC differentiation system is readily amenable to simple, clinically applicable modifications to improve hematopoietic output.
Quantitative modulation of WNT/β-catenin and activin/nodal/TGFβ signaling pathways by onetime addition of CHIR/SB molecules during mesodermal specification enhanced arterial VE and increased HOXA gene expression and definitive HSPC formation. However, consistent with previous studies [20] [21] [22] , this approach alone was insufficient to orchestrate the formation of functional HSCs and additional revisions to this system will be required. Addition of retinoid acid, a morphogen with a documented role in de-repressing HOXA genes [53] [54] [55] [56] and in embryonic HSPC development 57, 58 , may be required to complete the mesodermal patterning initiated by CHIR/SB. A recent study also revealed that overexpression ETS1, an EST family transcription factor involved in arterial fate control, or direct manipulation of MAPK/ERK signaling at the mesodermal stage led to an increase in arterial VE and definitive HSPCs 23 . It will be of interest to determine whether a combined approach to modulate MAPK/ERK, WNT/β-catenin and activin/nodal/TGFβ signaling pathways at this stage of differentiation can provide a synergy sufficient to further promote definitive hematopoiesis and the generation of engrafting HSCs.
In addition to the sequential emergence of developmental hematopoietic waves recognized in this study, our data also uncovered a nearly exclusive shift to definitive erythroid growth in later stages of differentiation that could be further enhanced by simple addition of CHIR/SB during mesodermal specification. Notably, this late erythropoietic upsurge occurred concomitantly with a rise in MSCs within the adherent monolayer. This observation coheres with the previously described erythroid commitment of human HSPCs co-cultured in the presence of MSCs 59, 60 . In one study 60 , a significant enrichment of genes implicated in heme metabolism and a parallel downregulation of pathways involved in lymphoid and myeloid differentiation were noted in cocultured CD34 + HSPCs. However, the precise molecular mechanism by which MSCs promote erythroid differentiation remain uncertain. The monolayer hematopoietic differentiation approach used in this study could provide a useful platform to identify prospective MSC-derived soluble factors implicated in erythroid maturation. Importantly, the STEMdiff TM system could be exploited 
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